Therapy Detail

Therapy Name Reolysin
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Reolysin REOLYSIN pelareorep RAS Inhibitor (Pan) 7 Reolysin (pelareorep) is a reovirus, which specifically infects and replicates in RAS-activated cells to induce apoptosis, and may also induce anti-tumor immune response (PMID: 29799479).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Reolysin Phase I Actionable In a Phase I study, Reolysin (pelareorep) demonstrated safety and some efficacy in patients with advanced solid tumors (PMID: 22886613). 22886613
KRAS mutant colorectal cancer sensitive Reolysin Preclinical - Cell culture Actionable In a preclinical study, colorectal cancer cells harboring a KRAS mutation demonstrated growth inhibition, cell membrane dysruption, induction of apoptosis, and G2/M arrest in culture when treated with Reolysin (pelareorep) (PMID: 24798549). 24798549
Clinical Trial Phase Therapies Title Recruitment Status
NCT01656538 Phase II Reolysin Paclitaxel A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Completed
NCT02620423 Phase I Gemcitabine Fluorouracil Irinotecan Reolysin Leucovorin Pembrolizumab Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma Completed
NCT01622543 Phase II Bevacizumab + FOLFOX Reolysin Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer Unknown status
NCT01619813 Phase II Docetaxel + Prednisone Reolysin Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer Completed